Predicting the short-term risk of diabetes in HIV-positive patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Petoumenos, Kathy ^a   Worm, Signe W ^b   Fontas, Eric ^c   Weber, Rainer ^d   De Wit, Stephane ^e   Bruyand, Mathias ^f   Reiss, Peter ^g   El Sadr, Wafaa ^h   D'Arminio Monforte, Antonella ⁱ   Friis Moller, Nina ^c   Lundgren, Jens D ^c,j   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f INSERM   (France)

^g STICHTING HIV MONITORING   (Netherlands)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ SAN PAOLO HOSPITAL   (Italy)

^j Mental Health Services CPH   (Denmark)

more..

Author keywords

Combination antiretroviral treatment; Diabetes mellitus; HIV; Risk equation

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; VALIDATION PROCESS; VIRUS LOAD; CHEMICALLY INDUCED DISORDER; DECISION SUPPORT SYSTEM; DRUG TOXICITY; EVALUATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84872956223     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17426     Document Type: Article

References (35)

1. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-32.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-9.
3. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-93.
4. Smith CJ, Levy I, Sabin CA, Kaya E, Johnson MA, Lipman MC. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med. 2004;5:88-92.
5. Santos J, Palacios R, Gonzalez M, Ruiz J, Marquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). Int J STD AIDS. 2005;16:677-80.
6. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7:404-10.
7. De Wit S, Sabin CA,Weber R,Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31:1224-9.
8. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIVinfected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007; 45:111-9.
9. Hughes CA, Cashin RP, Eurich DT, Houston S. Risk factors for new-onset diabetes mellitus in patients receiving protease inhibitor therapy. Can J InfectDis Med Microbiol. 2005;16:230-2.
10. Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227-34.
11. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375-83.
12. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179-84.
13. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV infected women. J Acquir Immune Defic Syndr. 2003;32:298-302.
14. Brambilla AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS. 2003;17:1993-5.
15. Garcia-Benayas T, Rendon AL, Rodriguez-Novoa S, Barrios A, Maida I, Blanco F, et al. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. AIDS Res Hum Retroviruses. 2006;22:333-7.
16. Modest GA, Fuller J. Abacavir and diabetes. N Engl J Med. 2001;344: 142-4.
17. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al.Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007;21:1739-45.
18. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136:575-81.
19. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB, Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068-74.
20. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev. 2000;16:164-71.
21. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27.
22. Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9:72-81.
23. Friis-Moller N, Thiebaut R, Reiss P,Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491-501.
24. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29 Suppl 1:S43-48.
26. ATP-III Panel. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
27. Stamler J, Vaccaro O, Neaton JD,Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44.
28. Royston P, Parmar MK, Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med. 2004;23:907-26.
29. May M, Royston P, Egger M, Justice AC, Sterne JA. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med. 2004;23:2375-98.
30. D'Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-7.
31. Hanley JA, McNeil BJ. The meaning and use of the area under a receiveroperating characteristic (ROC) curve. Radiology. 1982;143:29-36.
32. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed. 1994;39:387-94.
33. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology. 2004;40:115-9.
34. Noto D, Cefalu AB, Barbagallo CM, Falletta A, Ganci A, Sapienza M, et al. Prediction of incident type 2 diabetes mellitus based on a twenty-year followup of the Ventimiglia heart study. Acta Diabetol. 2012;49(2):145-51.
35. May M, Sterne JA, Shipley M, Brunner E, d'Agostino R, Whincup P, et al. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol. 2007;36:1309-18.